Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $43 to $46.
August 02, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical and raises the price target from $43 to $46.
The raised price target from $43 to $46 indicates a positive outlook from the analyst, which could lead to a short-term increase in the stock price. However, the Neutral rating suggests that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100